Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2006

01-10-2006 | Original Paper

Plasma Calprotectin Levels in Patients Suffering from Acute Pancreatitis

Authors: Antonio Carroccio, Pasquale Rocco, Pier Giorgio Rabitti, Lidia Di Prima, Giovanni Battista Forte, Angelo B. Cefalù, Franco Pisello, Girolamo Geraci, Generoso Uomo

Published in: Digestive Diseases and Sciences | Issue 10/2006

Login to get access

Abstract

Calprotectin (Cal) concentration is elevated in acute inflammatory reactions and its increase in the plasma suggests a diagnostic potential for Cal assay. This study aimed (a) to evaluate the Cal plasma levels in patients suffering from acute pancreatitis (AP) and (b) to assess whether early assay of Cal plasma levels can be helpful in assessment of the severity of AP. Forty-six consecutive patients, median age 45 years, suffering from a first attack of AP were recruited at two medical centers. Data collected on admission included age, sex, delay between pain onset and admission, and Glasgow score. A severe outcome was defined according to the Atlanta criteria. AP was defined as edematous or necrotic according to the CT findings. Plasma Cal and serum C reactive protein (CRP) were assayed in all patients within the first 24 hr after hospitalization. Sixty subjects suffering from blood hypertension were recruited as controls. Plasma Cal was measured by a commercial ELISA system. In all AP patients and in none of the controls, plasma Cal concentration was higher than the normal limit. Cal values in AP patients were significantly higher than in controls (P < 0.0001). There was not a statistically significant difference in Cal values between patients with severe and patients with mild AP. Plasma Cal values did not differ in necrotizing and edematous AP. During the follow-up plasma Cal was reassayed in six of the patients with abdominal fluid collection and the values were higher in the two patients with infected necrosis. We conclude that plasma Cal is elevated in patients with AP but it is not a useful marker for early prediction of pancreatitis severity. Further studies could evaluate its usefulness in pancreatic infected necrosis.
Literature
1.
go back to reference Fagerhol MK (1996) Nomenclature for proteins: Is calprotectin a proper name for the elusive myelomonocytic protein? J Clin Pathol Mol Pathol 49:M74–M79CrossRef Fagerhol MK (1996) Nomenclature for proteins: Is calprotectin a proper name for the elusive myelomonocytic protein? J Clin Pathol Mol Pathol 49:M74–M79CrossRef
2.
go back to reference Johne B, Fagerhol MK, Lyberg T, et al. (1997) Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 50:113–123PubMed Johne B, Fagerhol MK, Lyberg T, et al. (1997) Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 50:113–123PubMed
3.
go back to reference Brun JG, Ulvestad E, Fagerhol MK, Jonsson R (1994) Effects of human calprotectin on in vitro immunoglobulin synthesis. Scand J Immunol 40:675–680PubMedCrossRef Brun JG, Ulvestad E, Fagerhol MK, Jonsson R (1994) Effects of human calprotectin on in vitro immunoglobulin synthesis. Scand J Immunol 40:675–680PubMedCrossRef
4.
go back to reference Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzeg P, Fagerhol MK (1990) Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336:763–765PubMedCrossRef Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzeg P, Fagerhol MK (1990) Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336:763–765PubMedCrossRef
5.
go back to reference Berntzen HB, Olmez U, Fagerhol MK, Munthe E (1991) The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 18:1338–1339 Berntzen HB, Olmez U, Fagerhol MK, Munthe E (1991) The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 18:1338–1339
6.
go back to reference Kronborg O, Ugstad M, Fuglerud P, et al. (2000) Fecal calprotectin levels in a risk population for colorectal neoplasia. Gut 46:795–800PubMedCrossRef Kronborg O, Ugstad M, Fuglerud P, et al. (2000) Fecal calprotectin levels in a risk population for colorectal neoplasia. Gut 46:795–800PubMedCrossRef
7.
go back to reference Tibble J, Teahon K, Thjodleifsson B, et al. (2000) A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 47:506–513PubMedCrossRef Tibble J, Teahon K, Thjodleifsson B, et al. (2000) A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 47:506–513PubMedCrossRef
8.
go back to reference Carroccio A, Iacono G, Cottone M, et al. (2003) Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49(6):861–867PubMedCrossRef Carroccio A, Iacono G, Cottone M, et al. (2003) Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49(6):861–867PubMedCrossRef
9.
go back to reference Imrie CW, Benjamin IS, Ferguson JC, et al. (1978) A single-center double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 65:337–341PubMed Imrie CW, Benjamin IS, Ferguson JC, et al. (1978) A single-center double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 65:337–341PubMed
10.
go back to reference Bradley EL (1993) A clinically based classification system for acute pancreatitis. Arch Surg 128:586–590PubMed Bradley EL (1993) A clinically based classification system for acute pancreatitis. Arch Surg 128:586–590PubMed
11.
go back to reference Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Huges GRV (1993) Calprotectin in patients with systemic lupus erythematosous: relation to clinical and laboratory parameters of disease activity. Lupus 2:47–50PubMed Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Huges GRV (1993) Calprotectin in patients with systemic lupus erythematosous: relation to clinical and laboratory parameters of disease activity. Lupus 2:47–50PubMed
12.
go back to reference Golden BE, Clohessy PA, Russell G, Fagerhol MK (1996) Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 74:136–139PubMedCrossRef Golden BE, Clohessy PA, Russell G, Fagerhol MK (1996) Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 74:136–139PubMedCrossRef
13.
go back to reference Stockley RA, Dale I, Hill SL, Fagerhol MK (1984) Relationship of neutrophil cytoplasmic protein (L1) to acute and chronic lung disease. Scand J Clin Lab Invest 44:629–634PubMed Stockley RA, Dale I, Hill SL, Fagerhol MK (1984) Relationship of neutrophil cytoplasmic protein (L1) to acute and chronic lung disease. Scand J Clin Lab Invest 44:629–634PubMed
14.
go back to reference Fanjul M, Renaud W, Merten M, Guycrotte O, Hollande E, Figarella C (1995) Presence of MRP8 and MRP14 in pancreatic cells lines: differential expression and localization in CFPAC-1 cells. Am J Physiol Cell Physiol 37:C1241–C1251 Fanjul M, Renaud W, Merten M, Guycrotte O, Hollande E, Figarella C (1995) Presence of MRP8 and MRP14 in pancreatic cells lines: differential expression and localization in CFPAC-1 cells. Am J Physiol Cell Physiol 37:C1241–C1251
15.
go back to reference Appelros S, Petersson U, Toh S, Johnson C, Borgstrom A (2001) Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of severity of acute pancreatitis. Br J Surg 88:216–221PubMedCrossRef Appelros S, Petersson U, Toh S, Johnson C, Borgstrom A (2001) Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of severity of acute pancreatitis. Br J Surg 88:216–221PubMedCrossRef
16.
go back to reference Sandberg AA, Borgstrom A (2002) Early prediction of severity in acute pancreatitis. Is it possible? JOP J Pancreas (Online) 3:116–125 Sandberg AA, Borgstrom A (2002) Early prediction of severity in acute pancreatitis. Is it possible? JOP J Pancreas (Online) 3:116–125
17.
go back to reference Sainio V, Kemppainen E, Puolakkainen P, et al. (1995) Early antibiotic treatment in acute necrotising pancreatitis. Lancet 346:663–667PubMedCrossRef Sainio V, Kemppainen E, Puolakkainen P, et al. (1995) Early antibiotic treatment in acute necrotising pancreatitis. Lancet 346:663–667PubMedCrossRef
18.
go back to reference Messori A, Rampazzo R, Scrocaro G, et al. (1995) Effectiveness of gabexate mesilate in acute pancreatitis. A meta-analysis. Dig Dis Sci 40:734–738PubMedCrossRef Messori A, Rampazzo R, Scrocaro G, et al. (1995) Effectiveness of gabexate mesilate in acute pancreatitis. A meta-analysis. Dig Dis Sci 40:734–738PubMedCrossRef
19.
go back to reference Andriulli A, Leandro G, Clemente R, et al. (1998) Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 12:237–245PubMedCrossRef Andriulli A, Leandro G, Clemente R, et al. (1998) Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 12:237–245PubMedCrossRef
20.
go back to reference Cavallini G, Frulloni L (2001) Somatostatin and octreotide in acute pancreatitis: the never-ending story. Dig Liv Dis 33:192–201CrossRef Cavallini G, Frulloni L (2001) Somatostatin and octreotide in acute pancreatitis: the never-ending story. Dig Liv Dis 33:192–201CrossRef
21.
go back to reference Wilson C, Heads A, Shenkin A, Imrie CW (1989) C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 76:177–181PubMed Wilson C, Heads A, Shenkin A, Imrie CW (1989) C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 76:177–181PubMed
22.
go back to reference Neoptolemos JP, Kemppainen EA, Mayer JM, et al. (2000) Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet 355:1955–1960PubMedCrossRef Neoptolemos JP, Kemppainen EA, Mayer JM, et al. (2000) Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. Lancet 355:1955–1960PubMedCrossRef
Metadata
Title
Plasma Calprotectin Levels in Patients Suffering from Acute Pancreatitis
Authors
Antonio Carroccio
Pasquale Rocco
Pier Giorgio Rabitti
Lidia Di Prima
Giovanni Battista Forte
Angelo B. Cefalù
Franco Pisello
Girolamo Geraci
Generoso Uomo
Publication date
01-10-2006
Published in
Digestive Diseases and Sciences / Issue 10/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9078-4

Other articles of this Issue 10/2006

Digestive Diseases and Sciences 10/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.